goodfellowsmansfield.com

Tuesday, September 20, 2005

US doctors are to interview 12 patients with a view to performing the first ever transplant of a human face.

The Cleveland Clinic will choose between seven women and five men to find the person most suited for the experimental procedure, which is a radical and controversial solution to extreme facial scarring or disfigurement.

Having practiced the procedure on bodies donated for medical research, the Cleveland Clinic team believe they have a 50% chance of success. The procedure will not live up to science-fiction predictions and give the recipient the appearance of the donor; the underlying bone structure is the deciding factor in the final appearance. The new face will end up resembling neither the donor nor recipient.

Surgeons in several other countries have announced being ready to perform this procedure in the past. However, the risk and non life-threatening nature of disfigurement have meant that gaining approval for the groundbreaking surgery has been difficult. Like many other transplant operations, the recipient would be required to take drugs to prevent tissue rejection for the remainder of their life. These drugs can have side effects and carry their own risks involving the patient’s immune system.

[edit]

Tuesday, January 25, 2011

The sole United States manufacturer of a key component of lethal injections announced Friday that it will cease production of the drug, contributing to shortages and delaying executions.

Sodium thiopental, the first of a three drug cocktail used in 34 states to render the prisoner to be executed unconscious, was manufactured in Italy until Italian authorities stated that they would only license the manufacture if it was used for medical purposes and not, crucially, for executions.

In a statement, the company, Hospira, said that they have never condoned the use of their drug, marketed as ‘Pentothal’, in executions, and that they could not “prevent the drug from being diverted to departments of corrections for use in capital punishment procedures”.

The move means that the United States is without a viable supplier for sodium thiopental. Although many European countries manufacture the drug, which is primarily used in Europe as an anæsthetic, no manufacturer has been found that is willing to supply it for use in conjunction with the death penalty, the abolition of which has been lobbied by the EU since 2008.

The shortage means that executions in California and Oklahoma have been delayed, with Texas’ last remaining stocks of the drug due to expire in March, weeks before two scheduled executions. These delays are likely to be prolonged as the legal process of drawing up new drugs to be used for injections is lengthy. Pentobarbital, an alternative which used at the Dignitas clinic in Switzerland, is used for lethal injections in Oregon, and has started to be used by Oklahoma.

Hospira’s decision caused mixed reactions throughout the medical community, with the American Society of Anesthesiologists stating Monday that sodium thiopental is an “important and medically necessary anesthetic agent” that is a “first-line anesthetic in many cases”, citing geriatric and cardiovascular conditions, among others. It said that, although they disagree with the death penalty, “we also do not condone using the issue as the basis to place undue burdens on the distribution of this critical drug to the United States. It is an unfortunate irony that many more lives will be lost or put in jeopardy as a result of not having the drug available for its legitimate medical use.”

Saturday, June 25, 2005

Seven months after suspicions were first raised, United States Agriculture Secretary Mike Johanns confirmed that a second American cow has tested positive for BSE (also known as ‘mad cow disease’), as determined by a lab in Weybridge, England. The department believes that this cow was born in the United States.

The delay in confirmation followed two conflicting test results from last November. The “Western blot” test, which is a more sophisticated test, could have helped reach a final determination, but the U.S. refused to perform it in November. The department’s inspector general, Phyllis Fong, ordered the Western blot test in June without advising Johanns and by the time Johanns found out about it, the testing was under way.

Johanns was annoyed that the round of testing which confirmed “Mad Cow” had been ordered without him being consulted first.”I was asked by the Senate and the president to operate the department,” Johanns said. “I believe, in this area, very clearly, the secretary should be consulted, whoever the secretary is, before testing is undertaken. From my standpoint, I believe I was put there to operate the department and was very disappointed.”

A senior research associate with Consumers Union, Michael Hansen, said USDA officials “almost sound like some Keystone Kops.”

Johanns reassured Americans that they should not be afraid of eating beef, saying: “This animal was blocked from entering the food supply because of the firewalls we have in place. Americans have every reason to continue to be confident in the safety of our beef.”

On June 17, the Associated Press reported: “American cattle are eating chicken litter, cattle blood and restaurant leftovers that could help transmit mad cow disease — a gap in the U.S. defense that the Bush administration promised to close nearly 18 months ago.”

John Stauber, co-author of “Mad Cow USA: Could the Nightmare Happen Here?” said: “Once the cameras were turned off and the media coverage dissipated, then it’s been business as usual, no real reform, just keep feeding slaughterhouse waste. The entire U.S. policy is designed to protect the livestock industry’s access to slaughterhouse waste as cheap feed.”

Critics of the U.S. testing regimen said the fumbles this time increase their concerns about America’s screening process.

“How can we be sure they were really negative?” Craig Culp, a spokesman for the Center for Food Safety asked; “After all, (here is a cow that was) negative in November that is positive in June.”

The companies which render slaughter waste say new restrictions are not warranted. “We process about 50 billion pounds of product annually — in visual terms, that is a convoy of semi trucks, four lanes wide, running from New York to L.A. every year,” said Jim Hodges, president of the American Meat Institute Foundation.